NanoRepro AG (XTER:NN6) Piotroski F-Score: 7 (As of Jun. 29, 2026) — 75% Above Median


XTER:NN6 NanoRepro AG XTER:NN6
63 GF Score
Price €2.08
GF Value €1.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is NanoRepro AG Piotroski F-Score?

NanoRepro AG XTER:NN6 63 Piotroski F-Score is 7 as of Jun. 29, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates XTER:NN6 with a GF Score™ of 63/100 and a GF Value™ of €1.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 94.29% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NanoRepro AG has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for NanoRepro AG's Piotroski F-Score or its related term are showing as below:

XTER:NN6' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of NanoRepro AG was 7. The lowest was 3. And the median was 4.

NanoRepro AG  (XTER:NN6) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NanoRepro AG Piotroski F-Score Related Terms


NanoRepro AG Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for NanoRepro AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoRepro AG Piotroski F-Score Chart

NanoRepro AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 6.00 5.00 4.00 7.00

NanoRepro AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.00 0.00 7.00 0.00

XTER:NN6 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, NanoRepro AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoRepro AG Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NanoRepro AG's Piotroski F-Score falls into.


XTER:NN6
63GF Score
NanoRepro AG XTER:NN6
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was €-2.05 Mil.
Cash Flow from Operations was €9.86 Mil.
Revenue was €4.65 Mil.
Gross Profit was €2.95 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was (41.458 + 39.025) / 2 = €40.2415 Mil.
Total Assets at the begining of this year (Dec23) was €41.46 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €14.96 Mil.
Total Current Liabilities was €0.30 Mil.
Net Income was €-4.69 Mil.

Revenue was €3.25 Mil.
Gross Profit was €1.89 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was (49.475 + 41.458) / 2 = €45.4665 Mil.
Total Assets at the begining of last year (Dec22) was €49.48 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €35.41 Mil.
Total Current Liabilities was €0.67 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NanoRepro AG's current Net Income (TTM) was -2.05. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NanoRepro AG's current Cash Flow from Operations (TTM) was 9.86. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-2.046/41.458
=-0.04935115

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-4.685/49.475
=-0.09469429

NanoRepro AG's return on assets of this year was -0.04935115. NanoRepro AG's return on assets of last year was -0.09469429. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NanoRepro AG's current Net Income (TTM) was -2.05. NanoRepro AG's current Cash Flow from Operations (TTM) was 9.86. ==> 9.86 > -2.05 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0/40.2415
=0

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/45.4665
=0

NanoRepro AG's gearing of this year was 0. NanoRepro AG's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=14.956/0.299
=50.02006689

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=35.414/0.673
=52.62109955

NanoRepro AG's current ratio of this year was 50.02006689. NanoRepro AG's current ratio of last year was 52.62109955. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NanoRepro AG's number of shares in issue this year was 12.613. NanoRepro AG's number of shares in issue last year was 12.713. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.946/4.648
=0.633821

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.893/3.247
=0.58299969

NanoRepro AG's gross margin of this year was 0.633821. NanoRepro AG's gross margin of last year was 0.58299969. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=4.648/41.458
=0.11211346

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=3.247/49.475
=0.06562911

NanoRepro AG's asset turnover of this year was 0.11211346. NanoRepro AG's asset turnover of last year was 0.06562911. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+0+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NanoRepro AG has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
NanoRepro AG (XTER:NN6) has a Piotroski F-Score of 7 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NanoRepro AG and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, NanoRepro AG's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, NanoRepro AG ranks #12 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 5.7%.
Is NanoRepro AG's Piotroski F-Score too high?
NanoRepro AG's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. NanoRepro AG's value of 7 is 40% above this industry median. Based on the distribution chart, NanoRepro AG ranks #12 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #12 out of 210 companies for Piotroski F-Score. This places NanoRepro AG in the top 6% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. NanoRepro AG's value of 7 is 40% above this benchmark. Historically, NanoRepro AG's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, NanoRepro AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.01, compared to a current price of €2.08 — trading 105.9% above its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 40% above the Medical Diagnostics & Research industry median of 5.00. NanoRepro AG's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Piotroski F-Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NanoRepro AG (XTER:NN6) Overvalued in 2026?

Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued. The current stock price of €2.08 is trading 105.9% above its estimated GF Value™ of €1.01. GuruFocus considers NanoRepro AG to be Significantly Overvalued.

Key valuation signals for XTER:NN6:

  • Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: €1.01 vs. price of €2.08 (105.9% above fair value)
  • GF Score™: 63/100 with 6 warning signs
  • Industry Position: 40% above the Medical Diagnostics & Research median (#12 of 210)

No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NanoRepro AG Business Description

Address Untergasse 8, Marburg, DEU, 35037
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
63GF Score

Get the complete analysis for XTER:NN6

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€1.01
GF Value